Advertisement

European Journal of Clinical Pharmacology

, Volume 72, Issue 6, pp 737–746 | Cite as

Off-label use of the expensive orphan drug eculizumab in France 2009–2013 and the impact of literature: focus on the transplantation field

  • Johann Castañeda-SanabriaEmail author
  • David Hajage
  • Melisande Le Jouan
  • Anne Perozziello
  • Florence Tubach
Pharmacoepidemiology and Prescription

Abstract

Purpose

The orphan drug eculizumab (Soliris ®) is one of the most expensive in the world and based on expenditures is classed among the highest in France, a scenario suggestive of off-label use. Given its pharmacological properties, it is likely to be used in organ transplantation. Our purposes were to describe the consumption trends of eculizumab for off-label indications overall and in the organ transplantation field and to assess the impact of publications on the latter use.

Methods

We carried out a temporal ecological study within the French national hospitalization database (PMSI). First, the trend of eculizumab consumption (2009–2013) was compared to our estimate of the maximum on-label consumption (overall and for transplantation). Second, we evaluated the impact of the publications supporting the effectiveness of eculizumab in the transplantation field on temporal trends of eculizumab consumption.

Results

Eculizumab total consumption exceeded our estimate of the maximum on-label consumption since the end of 2011 and increased until the end of the study. The off-label consumption represented at least 50 % of the total consumption. The off-label consumption in organ transplantation also increased since 2011. The amount of publications grew through the study period, but overall, the evidence level remained low. Statistically, publications were neither associated with the drug consumption for transplantation in the long term nor in the short term.

Conclusion

Eculizumab started being notably used for off-label indications in France since the end of 2011, and this use increased until the end of the study. We found only low-level evidence concerning the off-label use of eculizumab in the transplantation field through the studied period.

Keywords

Eculizumab Off-label use Orphan drugs Transplantation Organ rejection Pharmaceutical spending 

Notes

Acknowledgments

Author contributions

Dr. J. Castaneda-Sanabria had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Castaneda-Sanabria, Hajage and Tubach are responsible for the study concept and design. Acquisition of the data was performed by Le Jouan, Perozziello and Castaneda-Sanabria. Castaneda-Sanabria, Perozziello, Hajage and Tubach analysed and interpreted the data. Castaneda-Sanabria drafted the manuscript. Critical revision of the manuscript for important intellectual content was performed by Hajage, Le Jouan, Perozziello and Tubach. Statistical analysis was performed by Castaneda-Sanabria, Hajage and Perozziello. Tubach and Hajage supervised the study.

Financial disclosure

This study was financed by the National Institute for Health and Medical Research (Inserm) Clinical Research and Clinical Epidemiology Center (CIC-EC) 1425 as a part of a research internship. This institution did not have any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

Previous presentations of the work

This work was partly presented as an oral communication at the 9th annual French speaking conference of clinical epidemiology (Epiclin) in Montpellier, France, April 20–22, 2015.

Compliance with ethical standards

Competing interest

All authors declare that they do not have any financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and any other relationships or activities that could appear to have influenced the submitted work.

Supplementary material

228_2016_2027_MOESM1_ESM.pdf (444 kb)
ESM 1 (PDF 444 kb)

References

  1. 1.
    Stafford RS (2012) Off-label use of drugs and medical devices: a review of policy implications. Clin Pharmacol Ther. doi: 10.1038/clpt.2012.22 PubMedGoogle Scholar
  2. 2.
    Gillick MR (2009) Controlling off-label medication use. Ann Intern Med 150:344–347. doi: 10.7326/0003-4819-150-5-200903030-00108 CrossRefPubMedGoogle Scholar
  3. 3.
    Dal Pan GJ (2012) Monitoring the safety of medicines used off-label. Clin Pharmacol Ther 91:787–795. doi: 10.1038/clpt.2012.24 CrossRefPubMedGoogle Scholar
  4. 4.
    Silverman E (2011) Setting the bar higher for off-label use of biologics. Biotechnol Healthc 8:14PubMedPubMedCentralGoogle Scholar
  5. 5.
    Buckeridge DL (2012) Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 172:781. doi: 10.1001/archinternmed.2012.340 PubMedGoogle Scholar
  6. 6.
    Albrecht J, Meves A, Bigby M (2005) Case reports and case series from Lancet had significant impact on medical literature. J Clin Epidemiol 58:1227–1232. doi: 10.1016/j.jclinepi.2005.04.003 CrossRefPubMedGoogle Scholar
  7. 7.
    Prasad V, Ho N (2014) Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? J Clin Epidemiol 67:361–363. doi: 10.1016/j.jclinepi.2013.11.009 CrossRefPubMedGoogle Scholar
  8. 8.
    Solitis’ European Public Assessment Report (EPAR). In: Eur. Med. Agence EMA. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000791/human_med_001055.jsp&mid=WC0b01ac058001d124. Accessed 22 Jun 2014
  9. 9.
    Orphanet (2015) Prevalence and incidence of rare diseases: bibliographic data. Orphanet Rep. Ser. 1:Google Scholar
  10. 10.
    Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V (2015) The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 16:207. doi: 10.1186/s12882-015-0195-1 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Soliris Monograph. In: Thériaque. http://www.theriaque.org/apps/contenu/accueil.php. Accessed 10 Mar 2013
  12. 12.
    Banque de données des médicaments autorisés. In: Agence Fédérale Médicam. Prod. Santé AFMPS. http://www.fagg-afmps.be/fr/items-HOME/Bases_de_donnees/. Accessed 10 Jan 2016
  13. 13.
    Schwabe U, Paffrath D (2015) Arzneiverordnungs-Report 2015. Springer Berlin Heidelberg, , BerlinCrossRefGoogle Scholar
  14. 14.
    Soliris® Monograph. In: pro.medicin. http://pro.medicin.dk/Medicin/Praeparater/4328. Accessed 10 Jan 2016
  15. 15.
    Soliris - Norwegian Medicines Agency. In: Legemiddelverket. http://www.legemiddelverket.no/Sider/default.aspx. Accessed 10 Jan 2016
  16. 16.
    Ministère des affaires sociales et de la santé, Ministère des finances et des comptes publics Circulaire N°DSS/SD1C/DGOS/PF2/2014/108 du 9 avril 2014 relative à la mise en œuvre en 2014 des nouvelles dispositions rapprochant la maîtrise des dépenses au titre des produits de santé des listes en sus et le contrat de bon usage. In: Legifrance. http://circulaires.legifrance.gouv.fr/pdf/2014/04/cir_38185.pdf. Accessed 13 Aug 2015
  17. 17.
    Ricklin D (1950) Lambris JD (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol Baltim Md 190:3831–3838. doi: 10.4049/jimmunol.1203487 Google Scholar
  18. 18.
    Syndrome Uremique et Hémolytique Atypique (SHUa). In: Orphanet Portail Mal. Rares Médicam. Orphelins. http://www.orpha.net/consor/cgi-bin/index.php. Accessed 21 Jun 2014
  19. 19.
    Powers K, Hanssens DM, Hser Y-I, Anglin MD (1991) Measuring the long-term effects of public policy: the case of narcotics use and property crime. Manag Sci 37:627–644. doi: 10.1287/mnsc.37.6.627 CrossRefGoogle Scholar
  20. 20.
    Said SE, Dickey DA (1984) Testing for unit roots in autoregressive-moving average models of unknown order. Biometrika 71:599–607. doi: 10.1093/biomet/71.3.599 CrossRefGoogle Scholar
  21. 21.
    Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA (2009) The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9:231–235. doi: 10.1111/j.1600-6143.2008.02451.x CrossRefPubMedGoogle Scholar
  22. 22.
    Durrbach A, Francois H, Beaudreuil S, Jacquet A, Charpentier B (2010) Advances in immunosuppression for renal transplantation. Nat Rev Nephrol 6:160–167. doi: 10.1038/nrneph.2009.233 CrossRefPubMedGoogle Scholar
  23. 23.
    Hamer R, Krishnan N, Zehnder D, Lowe D, Briggs D, Fletcher S, Lam FT, Kashi H, Tan LC, Imray C, Higgins R (2009) Treatment of acute antibody-mediated rejection with the complement inhibitor eculizumab. Transpl Int 22:114–114Google Scholar
  24. 24.
    Kaneku H (2010) Impact of donor-specific HLA antibodies in transplantation, a review of the literature published in the last three years. Clin Transpl 283–306.Google Scholar
  25. 25.
    Stegall MD (2010) Clinical management of renal transplant patients with donor-specific alloantibody: the state of the art. Clin Transpl 307–15Google Scholar
  26. 26.
    Stegall MD, Gloor JM (2010) Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 15:8–10. doi: 10.1097/MOT.0b013e3283342712 CrossRefPubMedGoogle Scholar
  27. 27.
    Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362:1744–1745. doi: 10.1056/NEJMc0910965 CrossRefPubMedGoogle Scholar
  28. 28.
    Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517–1523. doi: 10.1111/j.1600-6143.2010.03156.x CrossRefPubMedGoogle Scholar
  29. 29.
    Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, Montgomery RA (2010) Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 10:2154–2160. doi: 10.1111/j.1600-6143.2010.03191.x CrossRefPubMedGoogle Scholar
  30. 30.
    Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA (2010) Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 25:2035–2045 quiz 2045–8. doi: 10.1007/s00467-009-1386-4 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kaneku H (2011) Annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 311–8Google Scholar
  32. 32.
    Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK (2011) Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 12:579–592. doi: 10.1517/14656566.2011.525219 CrossRefPubMedGoogle Scholar
  33. 33.
    Marfo K, Lu A, Ling M, Akalin E (2011) Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6:922–936. doi: 10.2215/cjn.08140910 CrossRefPubMedGoogle Scholar
  34. 34.
    Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A (2011) Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation—a case report. Transplant Proc 43:2097–2101. doi: 10.1016/j.transproceed.2011.02.064 CrossRefPubMedGoogle Scholar
  35. 35.
    Hughes PD, Cohney SJ (2011) Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr Opin Organ Transplant 16:425–433. doi: 10.1097/MOT.0b013e3283489a5a CrossRefPubMedGoogle Scholar
  36. 36.
    Velik-Salchner C, Lederer W, Wiedermann FJ (2011) Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation. Lupus 20:772–772. doi: 10.1177/0961203310389099 CrossRefPubMedGoogle Scholar
  37. 37.
    Biglarnia AR, Nilsson B, Nilsson T, von Zur-Muhlen B, Wagner M, Berne C, Wanders A, Magnusson A, Tufveson G (2011) Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 24:E61–E66. doi: 10.1111/j.1432-2277.2011.01290.x CrossRefPubMedGoogle Scholar
  38. 38.
    Morath C, Kihm LP, Zeier M, Waldher R, Schmidt J, Leo A, Susal C, Kirschfink M (2011) Reversal of refractory antibody-mediated rejection in blood group incompatible kidney transplantation by eculizumab. Mol Immunol 48:1677–1677. doi: 10.1016/j.molimm.2011.06.255 CrossRefGoogle Scholar
  39. 39.
    van den Hoogen MWF, Hilbrands LB (2011) Use of monoclonal antibodies in renal transplantation. Immunotherapy 3:871–880. doi: 10.2217/imt.11.72 CrossRefPubMedGoogle Scholar
  40. 40.
    Barnett ANR, Hadjianastassiou VG, Shaw OJ, Das PP, O’Donnell PJ, Chowdhury P, Dorling A, Mamode N (2011) Eculizumab for salvage in post-transplant thrombotic microangiopathy. Transpl Int 24:153–153Google Scholar
  41. 41.
    Biglarnia AR, Nilsson B, Nilsson T, von Zur-Muehlen B, Tufveson G (2011) ABO-incompatible deceased-donor pancreas and kidney transplantation using a novel protocol including eculizumab and monitoring of complement function. Transpl Int 24:5–5CrossRefGoogle Scholar
  42. 42.
    Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Moll S, Martin PY, Villard J (2011) Eculizumab therapy in refractory recurrence of thrombotic micro angiopathy associated to anti-phospholipid antibodies after renal transplantation. Transpl Int 24:227–228Google Scholar
  43. 43.
    Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:2523–2527. doi: 10.1111/j.1600-6143.2011.03696.x CrossRefPubMedGoogle Scholar
  44. 44.
    Morath C, Kirschfink M, Waldherr R, Becker LE, Kihm LP, Schaier M, Schwenger V, Schmidt J, Hohenfellner M, Leo A, Opelz G, Susal C, Zeier M (2011) Reversal of refractory antibody-mediated rejection in ABO-incompatible kidney transplantation by eculizumab. Transpl Int 24:34–34Google Scholar
  45. 45.
    Wilson CH, Brown AL, White SA, Goodship THJ, Sheerin NS, Manas DM (2011) Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 92:E42–E43. doi: 10.1097/TP.0b013e318230c0bd CrossRefPubMedGoogle Scholar
  46. 46.
    Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405–2413. doi: 10.1111/j.1600-6143.2011.03757.x CrossRefPubMedGoogle Scholar
  47. 47.
    Roussey-Kesler G, Decramer S (2011) Perspectives in pediatric renal transplantation. Nephrol Ther 7:618–621. doi: 10.1016/j.nephro.2011.11.008 CrossRefPubMedGoogle Scholar
  48. 48.
    Stewart Z, Collins T, Konkowski B, Reed A, Thomas C (2012) Eculizumab rescue of ABO-incompatible kidney transplant with antibody-mediated rejection refractory to splenectomy and plasmapheresis. Am J Transplant 12:80–81Google Scholar
  49. 49.
    Burbach M, Ouali N, Ridel C, Dahan K, Brocheriou I, Superbielle C, Hertig A, Rondeau E (2012) Three case-reports of eculizumab-resistant acute humoral rejection. Transpl Int 25:23–23CrossRefGoogle Scholar
  50. 50.
    Blume OR, Yost SE, Kaplan B (2012) Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transpl 2012:201754. doi: 10.1155/2012/201754 Google Scholar
  51. 51.
    Galliford J, Chan K, Charif R, Roufosse C, Brookes P, Charif R, Willicombe M, Lawrence C, Hakim N, Papalois V, Cook HT, McLean A, Taube D (2012) Eculizumab prevents allograft loss from acute antibody mediated rejection in the short and medium term. Am J Transplant 12:83–83Google Scholar
  52. 52.
    McCaughan JA, O’Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 12:1046–1051. doi: 10.1111/j.1600-6143.2011.03923.x CrossRefGoogle Scholar
  53. 53.
    Fehr T, Gaspert A (2012) Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 25:623–632. doi: 10.1111/j.1432-2277.2012.01453.x CrossRefPubMedGoogle Scholar
  54. 54.
    Jackson AM, Kuperman MB, Montgomery RA (2012) Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 12:1643–1649. doi: 10.1111/j.1600-6143.2011.03955.x CrossRefPubMedGoogle Scholar
  55. 55.
    Suberbielle C, Corcos O, Hatem DC, Hertig A, Carmagnat M, Charron D, Panis Y, Joly F (2012) Treatment of refractory antibody mediated rejection with eculizumab in an adult with combined liver and small bowel transplantation. Tissue Antigens 79:495–496Google Scholar
  56. 56.
    Morath C, Opelz G, Zeier M, Susal C (2012) Recent developments in desensitization of crossmatch-positive kidney transplant recipients. Transplant Proc 44:1648–1651. doi: 10.1016/j.transproceed.2012.04.006 CrossRefPubMedGoogle Scholar
  57. 57.
    Marks SD (2012) New immunosuppressants in pediatric solid organ transplantation. Curr Opin Organ Transplant 17:503–508. doi: 10.1097/MOT.0b013e32835741cd CrossRefPubMedGoogle Scholar
  58. 58.
    Verma KP, Pan FF, Peter H (2012) Eculizumab in severe thrombotic microangiopathy after renal transplantation. Immunol Cell Biol 90:A25–A25Google Scholar
  59. 59.
    Pascual J, Perez-Saez MJ, Mir M, Crespo M (2012) Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplant Rev 26:280–290. doi: 10.1016/j.trre.2012.07.002 CrossRefGoogle Scholar
  60. 60.
    Gonzalez-Roncero F, Suner M, Bernal G, Cabello V, Toro M, Pereira P, Gentil MA (2012) Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 44:2690–2694. doi: 10.1016/j.transproceed.2012.09.038 CrossRefPubMedGoogle Scholar
  61. 61.
    Stegall MD, Chedid MF, Cornell LD (2012) The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 8:670–678. doi: 10.1038/nrneph.2012.212 CrossRefPubMedGoogle Scholar
  62. 62.
    Dawson KL, Parulekar A, Seethamraju H (2012) Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 31:1325–1326CrossRefPubMedGoogle Scholar
  63. 63.
    Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP (2012) Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 44:3033–3036. doi: 10.1016/j.transproceed.2012.03.053 CrossRefPubMedGoogle Scholar
  64. 64.
    Orandi BJ, Garonzik-Wang JM, Gupta N, Van Arendonk KJ, Lonze BE, Zachary AA, Alachkar N, Kraus ES, Locke JE, Nazarian SM, Dagher NN, Desai NM, Segev DL, Montgomery RM (2013) Eculizumab as salvage therapy for severe antibody-mediated rejection following hla-incompatible renal transplantation. Am J Transplant 13:77–78CrossRefGoogle Scholar
  65. 65.
    Cai JC, Qing X, Tan JM, Terasaki PI (2013) Humoral theory of transplantation: some hot topics. Br Med Bull 105:139–155. doi: 10.1093/bmb/lds037 CrossRefPubMedGoogle Scholar
  66. 66.
    de Latour RP, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, Socie G (2013) Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 161:279–280. doi: 10.1111/bjh.12202 CrossRefGoogle Scholar
  67. 67.
    Jordan S, Choi J, Villicana R, Peng A, Kahwaji J, Najjar R, Vo A (2013) Eculizumab (anti-C5) for treatment of severe antibody-mediated rejection (ABMR) and recurrent C3 glomerulonephritis in renal allografts: a single center experience. Am J Transplant 13:329–329CrossRefGoogle Scholar
  68. 68.
    Kocak B, Arpali E, Demiralp E, Yelken B, Karatas C, Gorcin S, Gorgulu N, Uzunalan M, Turkmen A, Kalayoglu M (2013) Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 45:1022–1025. doi: 10.1016/j.transproceed.2013.02.062 CrossRefPubMedGoogle Scholar
  69. 69.
    Kulkarni S, Kirkles-Smith N, Tomlin R, Formica R, Moeckel G, Pober J (2013) Eculizumab therapy for chronic antibody-mediated injury in kidney transplantation: an interim assessment. Am J Transplant 13:86–86CrossRefGoogle Scholar
  70. 70.
    Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, Socie G (2013) Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 161:279–280. doi: 10.1111/bjh.12202 CrossRefPubMedGoogle Scholar
  71. 71.
    Thampi S, Dvorak C, Matthay K, Horn B (2013) Eculizumab for the treatment of hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (ta-Tma). Pediatr Blood Cancer 60:S104–S105Google Scholar
  72. 72.
    Barnett ANR, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N (2013) The use of eculizumab in renal transplantation. Clin Transpl 27:E216–E229. doi: 10.1111/ctr.12102 CrossRefGoogle Scholar
  73. 73.
    Cornell LD (2013) Renal allograft pathology in the sensitized patient. Curr Opin Organ Transplant 18:327–336. doi: 10.1097/MOT.0b013e3283614c5a CrossRefPubMedGoogle Scholar
  74. 74.
    Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, Anglicheau D (2013) Eculizumab in renal transplantation. Transpl Rev Orlando 27:90–92. doi: 10.1016/j.trre.2013.04.002 CrossRefGoogle Scholar
  75. 75.
    Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noel LH, Guilbeau-Frugier C, Sberro-Soussan R, Del Bello A, Martinez F, Zuber J, Rostaing L, Legendre C (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:2179–2185. doi: 10.1111/ajt.12319 CrossRefPubMedGoogle Scholar
  76. 76.
    Burbach M, Suberbielle C, Ouali N, Dahan K, Brocheriou I, Ridel C, Mesnard L, Rondeau E, Hertig A (2013) Report on the inefficacy of eculizumab in two cases of severe antibody mediated rejection of renal grafts. Transpl Int 26:136–136Google Scholar
  77. 77.
    Cicora F, Roberti J, Mos F, Paz M (2013) Use of eculizumab in a highly hla-sensitized renal transplantation patient. Transpl Int 26:272–272Google Scholar
  78. 78.
    Cozzi E, Padalino M, Toscano G, Marson P, Murer L, Pettenazzo A, Sgarabotto D, Milanesi O, Angelini A, Seveso M, Gambino A, Tison T, Ruffoni E, Migoni A, Feltrin G, Kirk R, Piccolo G, De Silvestro G, Zanon GF, Giovanni S, Gerosa G (2013) Bortezomib associated with C5 inhibition with eculizumab enables combined cardiac-renal transplantation in a highly immunized child. Transpl Int 26:89–89Google Scholar
  79. 79.
    Turkmen A, Kocak B, Arpali E, Demiralp E, Gorcin S, Yelken B, Kalayoglu M (2013) Eculizumab in kidney transplantation: should we change our treatment algorithm? Transpl Int 26:175–175Google Scholar
  80. 80.
    Elias M, Beaudreuil S, Obada E, Poitou C, Weis L, Iamandi L, Mutinelli P, Charpentier B, Durrbach A, Francois H (2013) Eculizumab in antibody mediated rejection. Transpl Int 26:8–8CrossRefGoogle Scholar
  81. 81.
    Hardinger KL, Brennan DC (2013) Novel immunosuppressive agents in kidney transplantation. World J Transpl 3:68–77. doi: 10.5500/wjt.v3.i4.68 Google Scholar
  82. 82.
    Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2014) Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 99:922–929. doi: 10.3324/haematol.2013.093161 CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (2012) The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One 7:e31894. doi: 10.1371/journal.pone.0031894 CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Winthrop KL, Smolen JS (2011) Therapy: off-label biologics use and infection risk—the great unknown. Nat Rev Rheumatol 7:685–686. doi: 10.1038/nrrheum.2011.154 CrossRefPubMedGoogle Scholar
  85. 85.
    Duhamel G, Morelle A (2012) Evaluation du dispositif de financement des médicaments en sus des prestations d’hospitalisation dans les établissements de santé. Insp. Générale Aff. Soc. Contract No NRM2012-044PGoogle Scholar
  86. 86.
    Statens Serum Institut Medstat.dk. http://medstat.dk/. Accessed 10 Jan 2016
  87. 87.
    Institut National de la Statistique et des Etudes Economiques Insee - Population - Évolution de la population jusqu’en 2015. http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATnon02145%C2. Accessed 10 Jan 2016
  88. 88.
    Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562. doi: 10.2215/CJN.04760512 CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Alexion (2015) Alexion provides update on phase 2 clinical trial with eculizumab in antibody mediated rejection (AMR) in living-donor kidney transplant recipients. In: Alexion Pharm. Inc. http://news.alexionpharma.com/press-release/company-news/alexion-provides-update-phase-2-clinical-trial-eculizumab-antibody-mediat. Accessed 17 Aug 2015

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Johann Castañeda-Sanabria
    • 1
    • 2
    • 3
    Email author
  • David Hajage
    • 1
    • 2
    • 3
  • Melisande Le Jouan
    • 4
  • Anne Perozziello
    • 5
  • Florence Tubach
    • 1
    • 2
    • 3
  1. 1.APHP, Département d’Epidémiologie et Recherche Clinique CIC-EC 1425Centre de Pharmacoépidémiologie (Cephepi)ParisFrance
  2. 2.University Paris Diderot, Sorbonne Paris CitéUnité Mixte de Recherche (UMR) 1123: Epidémiologie clinique, évaluation économique et populations vulnérables (ECEVE)ParisFrance
  3. 3.Institut National de la Santé et de la Recherche Medicale (INSERM) CIC-EC 1425Unité Mixte de Recherche (UMR) 1123: Epidémiologie clinique, évaluation économique et populations vulnérables (ECEVE)ParisFrance
  4. 4.Observatoire Des Médicaments, des dispositifs médicaux et de l’innovation thérapeutique (OMEDIT) Île-de-FranceParisFrance
  5. 5.APHP, Hôpital BichatDépartement d’Information Médicale (DIM)ParisFrance

Personalised recommendations